专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3119425B1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
公开(公告)号：EP3119425B1
公开(公告)日：2020-09-23
申请号：EP15764851.0
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00

2. 发明公开

EP3811970A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 审中-实审转让
公开(公告)号：EP3811970A1
公开(公告)日：2021-04-28
申请号：EP20191324.1
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

3. 发明公开

EP3087101A4 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
公开(公告)号：EP3087101A4
公开(公告)日：2017-12-06
申请号：EP14872734
申请日：2014-12-19
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , BROGDON JENNIFER , ENGELS BORIS , GLASS DAVID JONATHAN , GRANDA BRIAN , HASTEWELL JOHN , LOEW ANDREAS , MANNICK JOAN , MILONE MICHAEL C , MURPHY LEON , SELLERS WILLIAM RAJ , SONG HUIJUAN , VASH BRIAN EDWARD , WEILER JAN , WU QILONG , ZHOU LI
发明人： BROGDON JENNIFER , ENGELS BORIS , GLASS DAVID JONATHAN , GRANDA BRIAN , HASTEWELL JOHN , LOEW ANDREAS , MANNICK JOAN , MILONE MICHAEL , MURPHY LEON , SELLERS WILLIAM RAJ , SONG HUIJUAN , VASH BRIAN EDWARD , WEILER JAN , WU QILONG , ZHOU LI
IPC分类号： C07K19/00 , A61K31/436 , A61K35/17 , C07K14/725 , C07K16/28 , C12N5/0783
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

4. 发明公开

EP3119425A4 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
公开(公告)号：EP3119425A4
公开(公告)日：2017-11-22
申请号：EP15764851
申请日：2015-03-13
申请人： NOVARTIS AG , UNIV PENNSYLVANIA , ENGELS BORIS
发明人： ENGELS BORIS , LOEW ANDREAS , MILONE MICHAEL C , ZHOU LI
IPC分类号： A61K39/00 , A61K38/00
CPC分类号： C07K16/2863 , A61K38/00 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/3955 , A61K2039/5156 , A61K2039/5158 , A61K2039/55561 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70575 , C07K16/00 , C07K16/28 , C07K16/2803 , C07K2317/22 , C07K2317/53 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/73 , C12N15/62
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

5. 发明公开

EP3119425A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
标题翻译：调节剂CHIMÄRER抗生素
公开(公告)号：EP3119425A1
公开(公告)日：2017-01-25
申请号：EP15764851.0
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译：提供与可调节嵌合抗原受体（RCAR），天然杀伤细胞受体CAR（NKR-CAR）和可调节NKR-CAR（RNKR-CAR）有关的组合物和方法，其中RCAR或RNKR-CAR的细胞内信号传导或增殖可以控制以优化RCAR / NKR-CAR或RNKR-CAR表达细胞的使用以提供免疫应答。可以将细胞工程化以表达RNKR-CAR或表达RCAR和NKR-CAR（例如抑制性NKR-CAR）。例如，RCAR或RNKR-CAR可以包含二聚转换开关，其在二聚化分子的存在下可以将细胞内信号结构域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域，或共刺激ECD域。 RCAR或RNKR-CAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

6. 发明公开

EP3087101A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
标题翻译：调节剂CHIMÄRER抗生素
公开(公告)号：EP3087101A1
公开(公告)日：2016-11-02
申请号：EP14872734.0
申请日：2014-12-19
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Brogdon, Jennifer , Engels, Boris , GLASS, David, Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , Milone, Michael C. , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS,William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译：提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。例如，RCAR可以包含二聚转换开关，其在存在二聚化分子时可以将细胞内信号转导域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式